Analysts also highlight that Sage's current cost structure is unsustainable for future profitability without greater than $900 million in end-user sales of Zurzuvae.

Sage intends to present detailed results from the STATUS Trial at an upcoming medical meeting ... "Risk Factors" in our most recent Quarterly Report on Form 10-Q, as well as discussions of ...

Sage Therapeutics has slightly tweaked the primary endpoint for a phase 3 trial of the Biogen-partnered depression drug zuranolone, a move analysts say is likely designed to avoid a miss on the ...

Biogen and Sage Therapeutics do not plan to conduct further studies for their neurological disorder drug after it failed in a mid-stage trial, the drugmakers said on Wednesday.